PubMed ID:
14681504
Public Release Type:
Journal
Publication Year: 2003
Affiliation: University of Texas Southwestern Medical Center, Dallas, TX 75390-9110, USA.
DOI:
https://doi.org/10.1056/NEJMoa030656
Authors:
Andriole GL Jr,
Bautista OM,
Clarke HS,
Crawford ED,
Diokno A,
Dixon CM,
Foley JP,
Foster HE,
Jacobs SC,
Kaplan SA,
Kreder KJ,
Kusek JW,
Lepor H,
Lieber MM,
Lucia MS,
McConnell JD,
McVary KT,
Medical Therapy of Prostatic Symptoms (MTOPS) Research Group,
Menon M,
Milam DF,
Miller GJ,
Nyberg LM Jr,
Ramsdell JW,
Roehrborn CG,
Schenkman NS,
Slawin KM,
Smith JA
Studies:
Medical Therapy of Prostatic Symptoms
Benign prostatic hyperplasia is commonly treated with alpha-adrenergic-receptor antagonists (alpha-blockers) or 5alpha-reductase inhibitors. The long-term effect of these drugs, singly or combined, on the risk of clinical progression is unknown.